Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells

International Immunopharmacology

Volumn 38, Issue , 2016, Pages 460-467

  Ye, Jun feng ^a   Lin, Yuan qiang ^a   Yu, Xiu hua ^b   Liu, Ming yuan ^a,c   Li, Yang ^a  

^a JILIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c YANGZHOU UNIVERSITY   (China)

Author keywords

CCL21; CIK cells; Combination therapy; IL15; Oncolytic adenoviruses

Indexed keywords

CONDITIONALLY REPLICATING ADENOVIRUS; INTERLEUKIN 15; SECONDARY LYMPHOID TISSUE CHEMOKINE; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE; TERT PROTEIN, HUMAN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CACO 2 CELL LINE; CANCER INHIBITION; COLON TUMOR; CYTOKINE INDUCED KILLER CELL; HELA CELL LINE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOVIRIDAE; ANIMAL; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG SCREENING; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; SCID MOUSE; TRANSPLANTATION; TUMOR CELL LINE; TUMOR VOLUME;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CHEMOKINE CCL21; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TELOMERASE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84976869348     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2016.06.028     Document Type: Article

References (33)

1. [1] Fujiwara, T., Kagawa, S., Tazawa, H., Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer. Curr. Pharm. Biotechnol. 13 (2012), 1809–1816.
2. [2] Darcy, P.K., Neeson, P., Yong, C.S., et al. Manipulating immune cells for adoptive immunotherapy of cancer. Curr. Opin. Immunol. 27 (2014), 46–52.
3. [3] Dudley, M.E., Rosenberg, S.A., Adoptive cell transfer therapy. Semin. Oncol. 34 (2007), 524–531.
4. [4] Rosenberg, S.A., Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol. 8 (2011), 577–585.
5. [5] June, C.H., Adoptive T, cell therapy for cancer in the clinic. J. Clin. Invest. 117 (2007), 1466–1476.
6. [6] Pievani, A., Borleri, G., Pende, D., et al. Dual-functional capability of CD3 + CD56 + CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 12 (2011), 3301–3310.
7. [7] Niam, M., Linn, Y.C., Fook, C.S., et al. Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy. Exp. Hematol. 39 (2011), 897–903.
8. [8] Pievani, A., Belussi, C., Klein, C., et al. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood 117 (2011), 510–518.
9. [9] Yan, Y., Xu, Y., Zhao, Y., et al. Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model. Tumour Biol. 2 (2014), 1113–1122.
10. [10] Yan, Y., Li, S., Jia, T., et al. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity. Tumour Biol. 6 (2015), 4535–4543.
11. [11] Mathis, J.M., Stoff-Khalili, M.A., Curiel, D.T., Oncolytic adenoviruses-selective retargeting to tumor cells. Oncogene 24 (2005), 7775–7791.
12. [12] Zhu, W., Wei, L., Zhang, H., et al. Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo. J. Exp. Clin. Cancer Res., 31, 2012, 51.
13. [13] Hu, Z.B., Wu, C.T., Wang, H., et al. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Cancer Gene Ther. 3 (2008), 173–182.
14. [14] Liu, G.Y., Li, Z.J., Li, Y., et al. Enhanced growth suppression of TERT-positive tumor cells by oncolytic adenovirus armed with CCL20 and CD40L. Int. Immunopharmacol. 28 (2015), 487–493.
15. [15] Zhao, D.X., Li, Z.J., Li, Y., et al. Enhanced antitumor immunity is elicited by adenovirus-mediated gene transfer of CCL21 and IL-15 in murine colon carcinomas. Cell. Immunol. 289 (2014), 155–161.
16. [16] Yang, Z., Zhang, Q., Xu, K., et al. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model. PLoS One, 7, 2012, e44802.
17. [17] Zeng, M., Smith, S.K., Siegel, F., et al. AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination. Biotechniques 31 (2001), 260–262.
18. [18] Luo, J., Deng, Z.L., Luo, X., et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat. Protoc. 2 (2007), 1236–1247.
19. [19] Janssen, J.M., Liu, J., Skokan, J., et al. Development of an AdEasy-based system to produce first- and second-generation adenoviral vectors with tropism for CAR- or CD46-positive cells. J Gene Med. 15 (2013), 1–11.
20. [20] Liu, G.Y., Jia, Q.Y., Li, Y., et al. Adenovirus-mediated CCL20/IL-15 gene transfer enhances antitumor immunity in mice. Immunobiology 219 (2014), 475–481.
21. [21] Finke, S., Trojaneck, B., Lefterova, P., et al. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3 + CD56 + immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Ther. 5 (1998), 31–39.
22. [22] Qiu, Z.H., Wu, C.T., Lao, M.F., et al. Growth suppression and immunogenicity enhancement of Hep-2 or primary laryngeal cancer cells by adenovirus-mediated co-transfer of human wild-type p53, granulocyte-macrophage colony-stimulating factor and B7-1 genes. Cancer Lett. 182 (2002), 147–154.
23. [23] Irving, J., Wang, Z., Powell, S., et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther. 11 (2004), 174–185.
24. [24] Uchino, J., Takayama, K., Harada, A., et al. Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment. Cancer Gene Ther. 12 (2005), 737–748.
25. [25] Varghese, S., Rabkin, S.D., Liu, R., et al. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther. 13 (2006), 253–265.
26. [26] Sharma, S., Zhu, L., Srivastava, M.K., et al. CCL21 chemokine therapy for lung cancer. Int Trends Immun. 1 (2013), 10–15.
27. [27] Yuan, L., Sherven, S., Maie, S.J., CCL21 cancer immunotherapy. Cancers (Basel) 6 (2014), 1098–1110.
28. [28] Zhou, S., Chen, L., Qin, J., et al. Depletion of CD4 + CD25 + regulatory T cells promotes CCL21-mediated antitumor immunity. PLoS One, 8, 2013, e73952.
29. [29] Kuate, S., Stefanou, D., Hoffmann, D., et al. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses. J. Gene Med. 6 (2004), 1197–1205.
30. [30] Gavin, P.C.M., Robert, D.S., Interferons, immunity and cancer immunoediting. Nat. Immunol. 6 (2006), 836–848.
31. [31] Zimmermann, V.S., Bondanza, A., Monno, A., et al. TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens. J. Immunol. 172 (2004), 2643–2650.
32. [32] Ma, Y., Zhang, Z., Tang, L., et al. Cytokine-induced killer cells in the treatment of patients with solid carcinom as: a systematic review and pooled analysis. Cytotherapy 14 (2012), 483–493.
33. [33] Niu, Q., Wang, W., Li, Y., et al. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int. Immunopharmacol. 11 (2011), 449–456.